Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05991323 · ClinicalTrials.gov registry record
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
A clinical trial of Prurigo Nodularis, sponsored by Sanofi.
- Active
- Registry status
- 100
- Enrollment target
- 20
- Study locations
NCT05991323: Active study of Prurigo Nodularis, sponsored by Sanofi.
NCT05991323 is a study of Prurigo Nodularis that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 100 participants, below the 222-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05991323, a study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (20)
California
- Center for Dermatology Clinical Research- Site Number : 8400002 - Fremont
- Halcyon Dermatology- Site Number : 8400023 - Laguna Hills
- Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015 - Rancho Santa Margarita
- Golden State Dermatology- Site Number : 8400014 - Walnut Creek
Michigan
- Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007 - Auburn Hills
- Derm Institute of Western Michigan- Site Number : 8400034 - Caledonia
- Dermatology Associates Western Michigan- Site Number : 8400033 - Grand Rapids
Arizona
- Medical Dermatology Specialists Site Number : 8400005 - Phoenix
- Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024 - Phoenix
Florida
- Total Vein And Skin, LLC- Site Number : 8400019 - Boynton Beach
- GSI Clinical Research- Site Number : 8400017 - Margate
Nevada
- Vivida Dermatology - Flamingo- Site Number : 8400013 - Las Vegas
- Las Vegas Dermatology- Site Number : 8400027 - Las Vegas
Georgia
- Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025 - Columbus
Indiana
- Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003 - Indianapolis
Missouri
- U.S. Dermatology Partners Lee's Summit- Site Number : 8400016 - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2026-09-22 |
What the registry record for NCT05991323 still lists
NCT05991323 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 222-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05991323 names 20 study sites across 12 states, led by California, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT05991323 about?
NCT05991323 is a clinical study titled "Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study". This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the ...
What is the current status of trial NCT05991323?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-12-12. Estimated completion is 2026-09-22.
What conditions does trial NCT05991323 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT05991323?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05991323?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05991323 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05991323's enrollment target sits among peer trials
100 10th of 14 higher than 5 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
RECRUITING
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI